| Soliris (eculizumab) / AstraZeneca |
NCT01192399: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients |
|
|
| Completed | 2 | 29 | NA | Eculizumab, Soliris | Alexion Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | 06/08 | 06/08 | | |
NCT01194804: E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients |
|
|
| Completed | 2 | 27 | NA | Eculizumab, Soliris | Alexion Pharmaceuticals, CMIC Co, Ltd. Japan | Paroxysmal Nocturnal Hemoglobinuria | 09/10 | 03/11 | | |
2016-002943-40: A Clinical Study with Investigational Drug, ALN-CC5, in patients with Paroxysmal Nocturnal Hemoglobinuria who are Inadequate Responders to Eculizumab Estudio clínico con fármaco en investigación, ALN-CC5, en pacientes con hemoglobinuria paroxística nocturna que presentan una respuesta insuficiente al eculizumab |
|
|
| Terminated | 2 | 15 | Europe | ALN-CC5, Solution for injection | Alnylam Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc | Paroxysmal nocturnal hemoglobinuria (PNH) Hemoglobinuria paroxística nocturna (HPN), Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal hematopoietic stem cell disorder of the blood characterized by destruction of red blood cells by the complement system. Hemoglobinuria paroxística nocturna es un raro trastorno clonal de células madre hematopoyéticas de la sangre caracterizado por destrucción de células rojas de sangre por el sistema del complemento., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 12 | Europe, US | Danicopan, Eculizumab, Soliris | Alexion Pharmaceuticals, Inc., Achillion, a wholly owned subsidiary of Alexion | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 09/19 | 01/23 | | |
|
|
NCT04888507: Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy |
|
|
| Completed | 2 | 6 | Europe | Pozelimab, REGN3918, Cemdisiran, ALN-CC5 | Regeneron Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | 05/22 | 05/23 | | |
| Terminated | 2 | 12 | Europe | BCX9930, Eculizumab, Soliris, Ravulizumab, Ultomiris, ALXN1210, ravulizumab-cwvz | BioCryst Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 09/23 | 09/23 | | |
NCT05646563: Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris |
|
|
| Not yet recruiting | 2 | 12 | NA | NM8074, Soliris, Eculizumab | NovelMed Therapeutics | Paroxysmal Nocturnal Hemoglobinuria | 08/26 | 01/27 | | |
NCT05731050: Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
|
| Not yet recruiting | 2 | 6 | NA | NM8074 | NovelMed Therapeutics | PNH - Paroxysmal Nocturnal Hemoglobinuria | 08/26 | 10/26 | | |
